CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.

By Sergio A. Quezada, K. Peggs, M. Curran, James P. Allison. Journal of Clinical Investigation, 2006

685 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/d4fcc4fe2fccd1e69eb540717d97280812f6494f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Oncology

Citations in the corpus

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4 (2013, background): “Importantly, the intratumor ratio of effector T cells to T reg cells was also increased, a finding that was previously shown to be a marker of a favorable immunological response to immunotherapy in murine tumor models (Quezada et al., 2006; Curran et al., 2010) and has been associated with improved ”
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors (2010, background): “CTLA-4, PD-1, or PD-L1 blockade increases CD8 T-cell-toTreg ratios within the tumor, which we have previously described as being predictive of therapeutical efficacy in the B16 melanoma model (14) (Fig.”
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma (2013, background): “2 C; Quezada et al., 2006; Hodi et al., 2008; Liakou et al., 2008), which is thought to drive tumor rejection given the anti- and pro-tumor growth activity of T eff and T reg cells, respectively (Griffiths et al., 2007; Quezada et al., 2008).”
Immunosuppressive strategies that are mediated by tumor cells. (2007, background): “showed that CTLA-4 blockade in combination with GM-CSF vaccination alters the intratumor balance of effector and regulatory T-cells (84).”
Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy (2014, background): “Scie effector to Treg ratios, which has been previously demonstrated to be a marker of a favorable immunological response to immunotherapy (29, 30).”
Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. (2007, background): “Manipulating an increase in the intratumoral ratio of effector to regulatory T cells in poorly immunogenic mice melanoma can overcome Treg-mediated suppression and tip the balance toward tumor rejection.(31) Therefore, a combination of depletion or attenuation of Tregs and concomitant stimulation of”
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies (2009, background): “Both cell lines have been previously described (Quezada et al., 2006).”
An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Non-Small Cell Lung Cancer (2013, background): “An increased ratio of effector to regulatory T cells following anti-CTLA-4 treatment is a hallmark of successful tumor rejection (23).”
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients (2008, background): “Together, these findings help clarify the immunologic and clinical effects of CTLA-4 antibody blockade in previously vaccinated patients and raise the possibility that selective targeting of antitumor Tregs may constitute a complementary strategy for combination therapy.”
The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses (2011, result): “However, other studies have shown an intact suppressive function in vitro of T Reg cells isolated from mic”
Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells (2013, background): “Previous data showed that anti-CTLA-4 antibody blockade results in expansion of Tregs in the lymph nodes of treated mice (9).”